Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors
Bonney brings over 30 years of life sciences industry leadership experience as company advances its covalent chemistry platform for targeted protein degradation and beyond
CAMBRIDGE, England — Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael Bonney as Chair of its Board of Directors. Mr. Bonney brings more than 30 years of life sciences industry leadership experience, including serving as President and Chief Executive Officer of Cubist Pharmaceuticals and Executive Chair of Alnylam Pharmaceuticals.
“Michael’s background, expertise, and successful leadership in guiding biopharmaceutical companies through critical milestones will be of tremendous value as we grow Dunad and advance our therapies to become leaders in the covalent therapeutics and targeted protein degradation space,” said Pearl Huang, Chief Executive Officer of Dunad Therapeutics. “His deep experience with executive and leadership development, particularly for therapeutics companies with emerging, cutting-edge modalities, will be a guiding force for myself and other members of our executive team.”
Mr. Bonney’s experience includes leading Cubist Pharmaceuticals to become the world’s leading antibacterial company before being purchased by Merck in January 2015 for $9.6b. Mr. Bonney was also Vice President of Sales and Marketing for Biogen, where he built the organization’s first commercial capability in the U.S. and launched Avonex, an injectable immunomodulator therapy for multiple sclerosis. More recently, Mr. Bonney held the position of Chief Executive Officer and Chair of Kaleido Biosciences, a company focused on developing microbiome therapies. In addition to Alnylam, Mr. Bonney has served as Board Chair of Magenta Therapeutics and Director of several biopharma companies including Sarepta Therapeutics, Bristol Myers Squibb, Celgene and Syros Pharmaceuticals.
“Dunad’s unique small molecule platform has the potential to develop covalent therapeutics for protein degradation that can broadly address a number of disease areas, which inspired my decision to join as Chair of the board,” said Mr. Bonney. “I am eager to work with Dunad’s impressive leadership team to overcome historic challenges in the field and advance therapies for previously undruggable targets.”
About Dunad Therapeutics
Dunad Therapeutics is a biopharmaceutical company with operations in Cambridge, England and Cambridge, Massachusetts developing covalent small molecule therapies based on novel insights from chemistry and protein degradation. Dunad’s proprietary, tunable platform is designed to discover and develop orally bioavailable, including CNS-accessible, therapeutics that have greater specificity and improved pharmacologic attributes compared with current therapies. For more information, please visit: www.dunadtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005127/en/
Ten Bridge Communications
Comments are closed.